Dravet syndrome.
epilepsy characterized by frequent febrile seizures and with onset before 1 year
Stoke, Biogen report four-year zorevunersen data showing sustained seizure control
At the European Epilepsy Congress in Athens, Stoke Therapeutics and Biogen presented four-year data from Phase 1/2a open-label extensions showing sustained cognitive and behavioral improvements plus durable seizure reductions for zorevunersen in Dravet syndrome, with results supporting ongoing Phase 3 EMPEROR and an anticipated 2027 readout. Separately, GRIN Therapeutics announced its on-site participation at the congress to discuss progress on GRIN-related neurodevelopmental disorders and potential collaborations, underscoring ongoing activity in epilepsy-focused biotech development.
Health · 7 sources · Sep 9, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Dravet syndrome
Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever. It is very difficult to treat with anticonvulsant medications. It often begins before one year of age, with six months being the age that seizures, characterized by prolonged convulsions and triggered by fever, usually begin.
Everything about Dravet syndrome →